ArticleBMC ophthalmology2026
Short-term efficacy of increasing 0.01% atropine administration frequency in controlling myopia progression in adolescents.
Article in BMC ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the efficacy and safety of increased administration frequency of 0.01% atropine eye drops in controlling myopia progression in adolescents, thereby providing evidence for optimizing clinical myopia prevention and control strategies.
methodsThis is a retrospective one arm clinical trial. Among the 108 initially enrolled children, 37 myopic participants (37 eyes, 7-12 years old) satisfying inclusion criteria entered the study from February to August 2025. The inclusion criterion was an axial length (AL) increase of ≥ 0.1 mm after 3 consecutive months of initial 0.01% atropine eye drops treatment. A single-group pre-post control design was adopted in this study, with the intervention divided into two phases (all intervention conditions were consistent except for the administration frequency): Initial intervention phase (Months 1-3): phase 1, All subjects received 0.01% atropine eye drops once daily at night; Intensive intervention phase (Months 4-6): phase 2, Based on the evaluation that AL growth was not optimally controlled in the initial phase, the administration frequency was adjusted to twice daily. Indicators including changes in AL, average corneal curvature (ACC), intraocular pressure (IOP), amplitude of accommodation (AMP), and adverse reactions.
resultsThe AL increase in the phase 1 during the first 3 months was 0.16 ± 0.07 mm, and then AL increase in phase 2 was 0.05 ± 0.08 mm during the subsequent 3 months, with AL growth retardation rate of 70.8%, showing a statistically significant difference (P < 0.001). There were no statistically significant differences in ACC and IOP between the two groups (P > 0.05). Although the AMP slightly decreased with increased administration frequency, it remained above 10D, meeting the needs of daily near vision. The incidence of photophobia in phase 2 was 16.2% (6/37), manifested only as mild photophobia which was tolerable.
conclusionAmong adolescents with poor myopia control under once-daily 0.01% atropine, increasing medication frequency to twice daily may slow AL progression without obvious safety concerns, which could serve as an alternative management option in clinical practice for myopia prevention and control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.